Takeheart Health Check      

552 Schacter M
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
Fund Clin Pharmacol 2004; 19: 117-35

553 Christiaens T
Cardiovascular Risk Tables. Estimating the risk is not the problem, using it to tailor treatment to individuals is.
BMJ 2008;336:1445-6

554 Laurie SJ
NICE's simplified approach to lipids will not work
BMJ 2008;336:1324

555 Jarrett DRJ
Time to label sodium in drug treatments?
BMJ 2008;336:1324

556 Montgomery B
Does paracetamol cause hypertension?
BMJ 2008;336:1324

557 Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
BMJ 2008;336:1475-82

558 Bhatnagar D, Soran H, Durrington P
Hypercholsterolaemia and its management
BMJ 2008;337:503-508

559 Wierzbicki AS, Humphries SE, Minhas R, on behalf of the Guidelines Develpment Group
Familial hypercholesterolaemia: summary of NICE guidance
BMJ 2008;337:509-510

560 Cooper A, O'Flynn N, on behalf of the Guidance Development Group
Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.
BMJ 2008;336:1246-8

561 Jackson R, Lynch J, Harper S.
Preventing Coronary Heart Disease
BMJ 2006;332:617-618

562 Jackson R, Wells S, Rodgers A.
Will screening individuals at high risk of cardiovascular events deliver large benefits?
BMJ 2008;337:a1371

563 Parkes G, Greenhalgh T, Griffin M, Dent R.
Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial
BMJ 2008

564 Godlee F.
A plea for broader perspectives on health
BMJ 2008;337:a1923

565 Entwistle V, Carter SM, Trevena L, Flitcroft K, Irwig L, McCaffrey K, Salkeld G,
Communicating about screening
BMJ 2008;337:a1591

566 Watts G.
What happened to the Polypill?
BMJ 2008:337;a1822

567 Scott IA.
Evaluating cardiovascular risk assessment for asymptomatic people.
BMJ 2009;338:a2844

568 de Ruijter W, Westendorp RGJ, Assendelft WJJ, den Elzen WPJ, de Craen AJM, le Cessie S, Gusekloo J
Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study
BMJ 2009;338:a3083

569 Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, Heerenga J, Witteman JC, Lansberg PJ, Kastelein JJP
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
BMJ 2008;337:a2423

570 Heart Disease and Stroke Statistics Dallas: American Heart Journal 2003. Read it

571 Statistical Fact Sheet — Populations, Asian/Pacific Islanders and Cardiovascular Diseases. Dallas: American Heart Association, 2004. Available at

.572 An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective cohort study.
Collins GS, Altman DG
BMJ 2009;339:b2584

573 QRISK or Framingham for predicting cardiovascular risk?
Editorial
BMJ 2009;339:b2673

574 Qureshi N, Humphries SE, Seed M, Minhas R, Minhas R
Identification and management of familial hypercholesterolaemia.
Br J Gen Pract 2009;59:773-778

575 National Institute for Clinical Excellence. NICE Guideline CG67. Lipid Modification.
London: NICE 2008. Read it

576 Wang YC, McPherson K, Marsh T, et al.
Health and economic burden of the projected obesity trends in the USA and UK.
Lancet 2011; 378(9793): 815-825.

577 Kaner EF, Beyer F, Dickinson HO, et al.
Brief interventions for excessive drinkers in primary health care settings.
Cochrane Database Syst Rev 2007;(2):CD004148

578 Editorial BMJ 347: 7/12/2013; BMJ 2013; 347: f7110